Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
Date:4/18/2011

idate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a proprietary novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... 25, 2014 BambooIndustry.com a famous bamboo ... years. Today, the company announces its multiple layer ... offer on these new products. , Bamboo panel is ... The multiple layer bamboo panel board features high quality ... and emissions free. The bamboo panel consists of multiple ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... shot, study finds , , TUESDAY, March 24 (HealthDay News) -- ... the 1980s and 1990s contained DNA from human papillomavirus type ... study. , It also found that women diagnosed with HPV16- ... than those diagnosed with cancers associated with other HPV types. ...
... Human Cytomegalovirus Stimulates Telomerase Activity in Tissue Culture ... triggers expression of the telomerase reverse transcriptase (hTERT) ... cells grown in culture. , HCMV has been ... mechanism by which the virus acts has been ...
... 24 Dr. Janet Neigel and the staff at the ... much-anticipated May 3rd, Pre-Mother,s Day Open House. The Center, located ... Jersey, will open its doors on May 3rd, 2009 between ... healthy solutions to their various cosmetic needs. The Pre-Mother,s Day ...
... ate higher amounts of soy during childhood had a 58 ... published in Cancer Epidemiology, Biomarkers and Prevention , a ... breast cancer incidence rates have been four to seven times ... in China or Japan. However, when Asian women migrate to ...
... about the threat of tuberculosis and the toll it takes ... Day. , The TB-HIV co-infection crisis is twice as ... 2007, there were at least 1.37 million cases of HIV-positive ... double the previous WHO estimates. , "A global health ...
... Clinical Specialists to Present Clinical Experience at American Burn ... Nephew Inc,s Advanced Wound Management division (LSE: SN; NYSE: ... titled "Optimizing Outcomes in Burn Care" at the 41st ... this symposium, top burn specialists will present their clinical ...
Cached Medicine News:Health News:HPV Data May Aid Vaccine's Effectiveness 2Health News:Also in the March 24 JNCI 2Health News:Also in the March 24 JNCI 3Health News:Also in the March 24 JNCI 4Health News:Also in the March 24 JNCI 5Health News:Also in the March 24 JNCI 6Health News:Spring Forward with a New You! The Neigel Center for Cosmetic and Laser Surgery Hosts Its May 3rd Pre-Mother's Day Open House! 2Health News:Eating soy early in life may reduce breast cancer among Asian women 2Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 3Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 4
The Bledsoe Basic Knee Brace offers a broad range of features that are unmatched by any other brace in its price range. Application of this brace is the easiest of any brace on the market....
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
McDavid® Patella Knee Support helps relieve the symptoms of chondromalacia patellar subluxation and patellar tendonitis. Features two medial and two lateral spring-steel stays. 3/16" thick neopre...
Medicine Products: